Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Sentinel lymph node biopsy in breast cancer: Techniques

Seth P Harlow, MD
Donald L Weaver, MD
Section Editor
Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C)
Deputy Editor
Wenliang Chen, MD, PhD


According to the sentinel lymph node (SLN) hypothesis, tumor cells migrating from a primary tumor metastasize to one or a few lymph nodes (LNs) before involving other LNs. Injection of blue dye and/or radiolabeled colloid into the skin and breast tissue around the area of the tumor or the subareolar area permits identification of one or more SLNs in the majority of patients. The status of the sentinel nodes accurately predicts the status of the remaining axillary LNs.

Sentinel lymph node biopsy (SLNB) is used to provide staging information and to assist in determining the need for axillary lymph node dissection (ALND) in breast cancer patients. A properly performed negative SLNB should accurately identify those patients without axillary node involvement, thereby obviating the need for a more morbid ALND. The risk of arm morbidity, particularly lymphedema, is significantly lower after SLNB than ALND. (See "Clinical features and diagnosis of peripheral lymphedema".)

The technique of SLNB in patients with breast cancer will be reviewed here. The indications, contraindications and outcomes of this approach are discussed separately. (See "Overview of sentinel lymph node biopsy in breast cancer".)


Radioactive colloid and/or blue dye is injected into the skin of the breast (intradermal, subdermal) or parenchyma of the breast, usually in the vicinity of the tumor or a subareolar location. These tracers then enter lymphatic channels, and passively flow to LNs. One or a few LNs are labeled, making it possible to identify those first receiving drainage from the tumor. The SLN can be variably located, but is usually within the low axilla (level I) [1]. (See "Management of the regional lymph nodes in breast cancer", section on 'Extent of dissection'.) Significant debate continues regarding the optimal agent for lymphatic mapping as well as the technique for use. Each surgeon needs to find the method that works best for them and be consistent in their practice.

Blue dye — The patient is prepped and draped in the operating room. The surgeon injects 3 to 5 mL of blue dye (classically isosulfan blue) around the tumor periphery, at the palpable edge of the biopsy cavity or into the subareolar plexus. It is important not to inject the dye into the tumor itself (because the lymphatics can be occluded by tumor) or into the seroma cavity following breast biopsy (as the seroma itself does not contain lymphatic channels). These errors in technique are likely to lead to a failure of mapping. Breast massage is then carried out for about five minutes to dilate breast lymphatics [2,3]. The use of isosulfan blue dye for SLNB is associated with severe anaphylactic reactions requiring resuscitation in 0.7 to 1.1 percent of cases [1,4-6]. Prophylactic treatment with 100 mg of hydrocortisone (or 20 mg of methylprednisolone or 4 mg of dexamethasone), 50 mg of diphenhydramine, and 20 mg of famotidine intravenously just before or at the induction of anesthesia appears to decrease the severity but not the incidence of dye reactions [4].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jun 2017. | This topic last updated: Feb 10, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007; 8:881.
  2. Schwartz GF, Giuliano AE, Veronesi U, Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 2002; 94:2542.
  3. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997; 15:2345.
  4. Raut CP, Hunt KK, Akins JS, et al. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer 2005; 104:692.
  5. Julian TB, Krag D, Brown A, et al. Preliminary technical results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients (abstract). Presented at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 9, 2004 (abstract 14).
  6. Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006; 13:491.
  7. Thevarajah S, Huston TL, Simmons RM. A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. Am J Surg 2005; 189:236.
  8. Bleicher RJ, Kloth DD, Robinson D, Axelrod P. Inflammatory cutaneous adverse effects of methylene blue dye injection for lymphatic mapping/sentinel lymphadenectomy. J Surg Oncol 2009; 99:356.
  9. Teknos D, Ramcharan A, Oluwole SF. Pulmonary edema associated with methylene blue dye administration during sentinel lymph node biopsy. J Natl Med Assoc 2008; 100:1483.
  10. Zakaria S, Hoskin TL, Degnim AC. Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer. Am J Surg 2008; 196:228.
  11. on http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm (Accessed on August 15, 2011).
  12. http://www.mylan.com/products/product-catalog/product-profile-page?id=09d1ee9e-4175-4df0-a74b-aa7635df83bd (Accessed on May 04, 2015).
  13. McMasters KM, Wong SL, Martin RC 2nd, et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg 2001; 233:676.
  14. Povoski SP, Olsen JO, Young DC, et al. Prospective randomized clinical trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol 2006; 13:1412.
  15. Motomura K, Komoike Y, Hasegawa Y, et al. Intradermal radioisotope injection is superior to subdermal injection for the identification of the sentinel node in breast cancer patients. J Surg Oncol 2003; 82:91.
  16. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23:7703.
  17. Shimazu K, Tamaki Y, Taguchi T, et al. Lymphoscintigraphic visualization of internal mammary nodes with subtumoral injection of radiocolloid in patients with breast cancer. Ann Surg 2003; 237:390.
  18. Tanis PJ, Deurloo EE, Valdés Olmos RA, et al. Single intralesional tracer dose for radio-guided excision of clinically occult breast cancer and sentinel node. Ann Surg Oncol 2001; 8:850.
  19. Doting MH, Jansen L, Nieweg OE, et al. Lymphatic mapping with intralesional tracer administration in breast carcinoma patients. Cancer 2000; 88:2546.
  20. Chagpar A, Martin RC 3rd, Chao C, et al. Validation of subareolar and periareolar injection techniques for breast sentinel lymph node biopsy. Arch Surg 2004; 139:614.
  21. Suami H, Pan WR, Mann GB, Taylor GI. The lymphatic anatomy of the breast and its implications for sentinel lymph node biopsy: a human cadaver study. Ann Surg Oncol 2008; 15:863.
  22. Uren RF, Howman-Giles R, Chung D, Thompson JF. Nuclear medicine aspects of melanoma and breast lymphatic mapping. Semin Oncol 2004; 31:338.
  23. Derossis AM, Fey J, Yeung H, et al. A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer. J Am Coll Surg 2001; 193:473.
  24. Hutchinson JR, Chagpar AB, Scoggins CR, et al. Surgeon and community factors affecting breast cancer sentinel lymph node biopsy. Am J Surg 2005; 190:903.
  25. McMasters KM, Wong SL, Tuttle TM, et al. Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel lymph nodes. Ann Surg 2000; 231:724.
  26. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997; 349:1864.
  27. Crossin JA, Johnson AC, Stewart PB, Turner WW Jr. Gamma-probe-guided resection of the sentinel lymph node in breast cancer. Am Surg 1998; 64:666.
  28. Morrow M, Rademaker AW, Bethke KP, et al. Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery 1999; 126:714.
  29. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276:1818.
  30. McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000; 18:2560.
  31. Cody HS 3rd, Fey J, Akhurst T, et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol 2001; 8:13.
  32. Xiong L, Gazyakan E, Yang W, et al. Indocyanine green fluorescence-guided sentinel node biopsy: a meta-analysis on detection rate and diagnostic performance. Eur J Surg Oncol 2014; 40:843.
  33. Samorani D, Fogacci T, Panzini I, et al. The use of indocyanine green to detect sentinel nodes in breast cancer: a prospective study. Eur J Surg Oncol 2015; 41:64.
  34. Rubio IT, Diaz-Botero S, Esgueva A, et al. The superparamagnetic iron oxide is equivalent to the Tc99 radiotracer method for identifying the sentinel lymph node in breast cancer. Eur J Surg Oncol 2015; 41:46.
  35. Douek M, Klaase J, Monypenny I, et al. Sentinel node biopsy using a magnetic tracer versus standard technique: the SentiMAG Multicentre Trial. Ann Surg Oncol 2014; 21:1237.
  36. Thill M, Kurylcio A, Welter R, et al. The Central-European SentiMag study: sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotope. Breast 2014; 23:175.
  37. Ahmed M, Purushotham AD, Douek M. Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review. Lancet Oncol 2014; 15:e351.
  38. Martin RC 2nd, Edwards MJ, Wong SL, et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group. Surgery 2000; 128:139.
  39. Liu LC, Lang JE, Jenkins T, et al. Is it necessary to harvest additional lymph nodes after resection of the most radioactive sentinel lymph node in breast cancer? J Am Coll Surg 2008; 207:853.
  40. Chung A, Yu J, Stempel M, et al. Is the "10% rule" equally valid for all subsets of sentinel-node-positive breast cancer patients? Ann Surg Oncol 2008; 15:2728.
  41. Hill AD, Tran KN, Akhurst T, et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg 1999; 229:528.
  42. Motomura K, Nagumo S, Komoike Y, et al. Accuracy of imprint cytology for intraoperative diagnosis of sentinel node metastases in breast cancer. Ann Surg 2008; 247:839.
  43. Krishnamurthy S, Meric-Bernstam F, Lucci A, et al. A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer 2009; 115:1555.
  44. Vanderveen KA, Ramsamooj R, Bold RJ. A prospective, blinded trial of touch prep analysis versus frozen section for intraoperative evaluation of sentinel lymph nodes in breast cancer. Ann Surg Oncol 2008; 15:2006.
  45. Langer I, Guller U, Berclaz G, et al. Accuracy of frozen section of sentinel lymph nodes: a prospective analysis of 659 breast cancer patients of the Swiss multicenter study. Breast Cancer Res Treat 2009; 113:129.
  46. Olson JA Jr, McCall LM, Beitsch P, et al. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol 2008; 26:3530.
  47. Viale G, Dell'Orto P, Biasi MO, et al. Comparative evaluation of an extensive histopathologic examination and a real-time reverse-transcription-polymerase chain reaction assay for mammaglobin and cytokeratin 19 on axillary sentinel lymph nodes of breast carcinoma patients. Ann Surg 2008; 247:136.
  48. Patani N, Mokbel K. The clinical significance of sentinel lymph node micrometastasis in breast cancer. Breast Cancer Res Treat 2009; 114:393.
  49. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer--a multicenter validation study. N Engl J Med 1998; 339:941.
  50. Guidelines from the American Society of Breast Surgeons www.breastsurgeons.org/officialstmts/sentinel.shtml (Accessed on September 13, 2005).
  51. Cox CE, Haddad F, Bass S, et al. Lymphatic mapping in the treatment of breast cancer. Oncology (Williston Park) 1998; 12:1283.
  52. Morton DL. Intraoperative lymphatic mapping and sentinel lymphadenectomy: community standard care or clinical investigation? Cancer J Sci Am 1997; 3:328.
  53. Euhus DM, Peters GN, Leitch AM, et al. Validating the performance of the mammary sentinel lymph node team. J Surg Oncol 2002; 79:209.
  54. Weaver DL. Sentinel lymph node biopsy in breast cancer: creating controversy and defining new standards. Adv Anat Pathol 2001; 8:65.
  55. Harlow SP, Krag DN, Julian TB, et al. Prerandomization Surgical Training for the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial: a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer. Ann Surg 2005; 241:48.